|Day Low/High||62.15 / 62.92|
|52 Wk Low/High||47.97 / 65.46|
Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono...
Here's how to trade seven of the most active stocks on the market this week.
Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.
Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.
Don't worry about a little selloff, says Jim Cramer. The data and earnings signal an improving economy.
The Merck Foundation (Foundation) and the Extension for Community Healthcare Outcomes (ECHO) Institute™ at the University of New Mexico Health Sciences Center announced today that the Foundation has provided a grant...
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.
Cramer shares his views on the pajama traders, and talks turkey about pet stocks.
Doug Kass shares his thoughts on animal spirits, and discusses his astonishment at some rising optimism.
Merck has 'all the momentum right now,' Lebenthal Asset Management CEO Jim Lebenthal said.
Rising drugs prices are a concern to Donald Trump but we can't let development of 'wonder drugs' slow in the health care sector, Cramer said.
Unusual volume flow could mean a spike in volatility. Here's a technical look at how to trade six stocks, including Smucker's and Merck.
Here are Thursday's top research calls, including upgrades for Bank of America, Merck and Morgan Stanley, and a downgrade for Valero.
It happened in the wake of Merck's latest drug approval.
Like President-elect Donald Trump's first press conference since securing victory, Wall Street's trading on Wednesday was unpredictable.
The Nasdaq falls from records in a volatile session following President-elect Donald Trump's first press conference since winning the election.
He's never really been a stock market guy anyway.
U.S. stocks fluctuated Wednesday after President-elect Trump targets the biotech industry in his first press conference since July.
Merck's lung cancer treatment will get a speedy review by the FDA, but it 'knows better than to go out and give false hope,' TheStreet's Jim Cramer said.
Here's a technical look on how to trade seven of today's most active stocks.
The Nasdaq takes a turn lower on Wednesday as President-elect Donald Trump targets the biotech and pharmaceutical industry in a press conference.
The terror that the futures struck, rightly or wrongly, has disappeared.
While there remains many unknowns about the specifics of possible legislation, CEO Alex Gorsky suggested that tax reform and repatriation could be a major game changer for J&J.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.
Animal health and oncology deal activity is heating up in 2017.
These four Dow components (and eight others I'm watching) are nowhere near record highs.
The companies will study epacadostat in tandem with Merck's Keytruda in patients with non-small cell lung, renal, bladder and head and neck cancers.